Methylsulfonic apatinib

PreclinicalSmall molecule

PPeking University People's Hospital

Methylsulfonic apatinib is one of 9 small molecule programs targeting Advanced Sarcoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced SarcomaCompleted

Advanced SarcomaPreclinical

Completed

Competition

Competitive Landscape

8 competitors in Advanced Sarcoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

4 2

Opdivo

Bristol-Myers Squibb

Phase 2

3 3

Adriamycin

Pfizer

Phase 2

2 4

Keytruda

Merck & Co.

Phase 2

2 5

Taxotere

AAvyxa

Phase 2

3 6

Cytoxan

BBaxter Healthcare Corporation

Phase 2

2 7

Fludara

Sanofi

Phase 1

1 8

APX005M

BBioNTech US Inc.

Phase 2

1 9

Methylsulfonic apatinib

PPeking University People's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced Sarcoma1 trial

Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use

Completed·PPeking University People's Hospital·N/A·NCT03491371·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methylsulfonic apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methylsulfonic apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methylsulfonic apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University People's Hospital

Methylsulfonic apatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced Sarcoma1 trial

References

Drug Info

Quick Facts

Related News